NRXP
NRX Pharmaceuticals Inc
2.90$
+2.4%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.8% | 94.1% | 88.4% | 92.7% | 92.0% | 90.4% | 95.6% | 94.9% | 79.7% | 68.6% | 61.8% | 85.4% | |
| 67.9% | 62.8% | 34.8% | 36.1% | 36.9% | 39.5% | 73.1% | 60.1% | 47.9% | 60.2% | 56.4% | 78.1% | |
| 67.9% | 62.8% | 34.8% | 36.1% | 36.9% | 39.5% | 73.1% | 60.1% | 47.9% | 60.2% | 56.4% | 78.1% | |
| 0.0% | 0.1% | 0.2% | 0.1% | 0.1% | 0.0% | – | – | 22.2% | 1.2% | 1.5% | 0.6% | |
| – | -0.1% | -0.2% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | 0.0% | – | – | 4.1% | 13.8% | 15.1% | 5.2% | |
| – | – | – | – | – | – | – | – | 11.8% | 7.1% | 7.4% | 2.4% | |
| 147.4% | 260.4% | 497.8% | 449.4% | 521.8% | 736.1% | 431.5% | 836.2% | 271.7% | 223.0% | 216.1% | 100.5% | |
| 147.4% | 260.4% | 497.8% | 449.4% | 454.9% | 598.8% | 431.5% | 836.2% | 270.7% | 220.6% | 211.5% | 99.2% | |
| 76.8% | 125.2% | 179.0% | 163.3% | 82.6% | 42.9% | 110.6% | 211.5% | 68.4% | 2.4% | 3.3% | 2.3% | |
| 27.7% | 63.3% | 165.4% | 95.3% | 109.1% | 113.1% | 56.8% | 75.0% | 28.4% | 33.0% | 37.0% | 9.2% | |
| – | – | – | – | 66.9% | 137.3% | – | – | – | – | – | – | |
| -47.4% | -160.4% | -397.8% | -349.4% | -421.8% | -636.1% | -331.5% | -736.2% | -171.7% | -123.0% | -116.1% | -0.5% | |
| -1,897.9% | -3,460.7% | -6,855.2% | -5,083.1% | -6,033.1% | -7,621.8% | -3,738.9% | -6,229.1% | -2,048.9% | -2,368.7% | -2,590.3% | -951.0% | |
| 62.5% | 1,147.2% | 233.7% | 199.8% | 245.9% | 288.1% | 216.2% | 370.7% | 148.2% | 244.9% | 271.6% | 110.2% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.